Clinical trials: Epithelial Mesothelioma
Malignant Pleural Mesothelioma
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol.
- Trial name
- NCT00886028
- Testing
- Liposomal doxorubicin, Cisplatin
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- National Institute of Cancerología
Pleural Mesothelioma
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung).
- Trial name
- NCT02414945
- Testing
- Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Mesothelioma
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
The purpose of this research study is to investigate the possibility that a person's genes put a person at a higher risk of developing mesothelioma.
- Trial name
- NCT01590472
- Where
- 6 sites in United States
- Volunteers
- 69 people
- Sponsor
- Wake Forest University
Malignant Pleural Mesothelioma
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma
- Trial name
- N08CPA (NCT01211275)
- Testing
- axitinib, chemotherapy
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Pleural Mesothelioma
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the safety of combining chemotherapy at different doses with a specific type of radiation therapy delivered to the entire lining of the lung to find out what effects, if any, it has on…
- Trial name
- NCT02639767
- Testing
- Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
- Where
- 6 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer, Mesothelioma
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
The purpose of this study is to establish the safest doses of an investigational drug called MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer.
- Conditions
- Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00325494
- Testing
- MORAb-009
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Morphotek
Clinical Trial, Phase I, Neuroendocrine Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
- Conditions
- Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
- Trial name
- LuPARP (NCT04375267)
- Testing
- 177Lu-DOTA-TATE + olaparib
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Malignant Pleural Mesothelioma, Advanced
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Aim of this study is to provide the "proof of concept" of efficacy and tolerability of lurbinectedin monotherapy in progressive malignant mesotheliomas.
- Trial name
- NCT03213301
- Testing
- Lurbinectedin
- Where
- 8 sites in Italy, Switzerland
- Volunteers
- 42 people
- Sponsor
- Swiss Cancer Institute
Tumors With CDK4/6 Pathway Activation
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT02187783)
- Testing
- LEE011
- Where
- 61 sites in United States
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Locally Advanced Solid Tumor
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05275478
- Testing
- TNG908
- Where
- 20 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Tango Therapeutics, Inc.
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed.
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant
- Trial name
- NCT05375825
- Testing
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
NSCLC, Mesothelioma
Folinic Acid for Prevention of Pemetrexed-induced Toxicity
Objective The main objective is to evaluate the haematological toxicity in patients who use pemetrexed with and without rescue therapy with folinic acid.
- Conditions
- NSCLC, Mesothelioma, Thymoma
- Trial name
- FLEX (NCT06010277)
- Testing
- Folinic acid
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Amphia Hospital
Solid Tumor
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors.
- Trial name
- NCT03975387
- Testing
- ASTX295
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Taiho Oncology, Inc.
Malignant Pleural Mesothelioma
Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis (median survival <13 months), and high resistance to chemotherapy.
- Trial name
- MesoPDT (NCT02662504)
- Testing
- photodynamic therapy (PDT), thoracic surgery Pleurectomy / extended Decortication, Adjuvant chemotherapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Lille
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Pleural Mesothelioma, Treatment Response
Evaluation of Response by FLT PET in Mesothelioma
Pleural mesothelioma (MPM) is an aggressive tumor that affects the pleura and originates from mesothelial cells. If untreated, median survival is 4-12 months following diagnosis.
- Conditions
- Pleural Mesothelioma, Treatment Response, Chemotherapy Effect
- Trial name
- FLT-MM (NCT06410625)
- Testing
- FLT PET imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Ankara University
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-II
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-II (NCT03655821)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Radboud University Medical Center
Malignant Mesothelioma
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00458913
- Testing
- bortezomib, cisplatin
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Mesothelioma
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
The objective of this phase 2 study is to evaluate the feasibility of an early palliative care intervention for metastatic cancer patients.
- Conditions
- Lung Cancer, Mesothelioma, Pancreas Cancer, Gastric Cancer
- Trial name
- NCT02078700
- Testing
- The early palliative care programme
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS